Journal
BIOCHEMICAL GENETICS
Volume 59, Issue 2, Pages 516-530Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10528-020-10014-x
Keywords
Cervical cancer (CC); Proliferation; Invasion; Molecular target
Ask authors/readers for more resources
AKR1C1, which is highly expressed in human cervical cancer tissues, correlates with clinical characteristics and plays a regulatory role in the proliferation and invasion of cervical cancer cells. It has the potential to be a molecular target for cervical cancer treatment.
Cervical cancer (CC) is a common gynecological malignancy, accounting for 10% of all gynecological cancers. Recently, targeted therapy for CC has shown unprecedented advantages. To improve CC patients' prognosis, there are still urgent needs to develop more promising therapeutic targets. Aldo-keto reductase 1 family member C1 (AKR1C1) is a type of aldosterone reductase and plays a regulatory role in a variety of key metabolic pathways. Several studies indicated that AKR1C1 was highly expressed in a series of tumors, and participated in the progression of these tumors. However, the possible effects of AKR1C1 on CC progression remain unclear. Herein, we revealed AKR1C1 was highly expressed in human CC tissues and correlated with the clinical characteristics of patients with CC. AKR1C1 could regulate the proliferation and invasion of cervical cancer cells in vitro. Further experiments showed that AKR1C1 could regulate TWIST1 expression and AKT pathway. In summary, we confirmed the involvement of AKR1C1 in CC progression, and therefore AKR1C1 may have the potential to be a molecular target for CC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available